JNJ-42160443 3 mg + JNJ-42160443 1 mg + JNJ-42160443 6 mg/3mg + JNJ-42160443 10 mg + Matching Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Low Back Pain
Conditions
Low Back Pain, Low Back Pain, Recurrent
Trial Timeline
Sep 1, 2009 → May 1, 2011
NCT ID
NCT00973024About JNJ-42160443 3 mg + JNJ-42160443 1 mg + JNJ-42160443 6 mg/3mg + JNJ-42160443 10 mg + Matching Placebo
JNJ-42160443 3 mg + JNJ-42160443 1 mg + JNJ-42160443 6 mg/3mg + JNJ-42160443 10 mg + Matching Placebo is a phase 2 stage product being developed by Johnson & Johnson for Low Back Pain. The current trial status is terminated. This product is registered under clinical trial identifier NCT00973024. Target conditions include Low Back Pain, Low Back Pain, Recurrent.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00973024 | Phase 2 | Terminated |
Competing Products
20 competing products in Low Back Pain